Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neurofibromatosis 1 19Melanoma 11Neurofibroma, Plexiform 10Lung Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Breast Neoplasms 7Solid Tumours 5Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Rectal Neoplasms 3Neurofibrosarcoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Renal Insufficiency 1

Interventions

aldesleukin 42Sunitinib 39Cyclophosphamide 30Nivolumab 27Everolimus 27pembrolizumab 26Interferon-alpha 25Bevacizumab 22Sorafenib 21Interleukin-2 20fludarabine phosphate 19Filgrastim 18Ipilimumab 17Radiotherapy 16Axitinib 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14fludarabine 11Radiosurgery 11Doxorubicin 11Carboplatin 11temsirolimus 10Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8belzutifan 8atezolizumab 8Fluorouracil 8pazopanib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Kidney Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡